Live from Open Targets Platform, fetched 2026-11-12 01:55 UTC. Every row links to its source record.

IL33 interleukin 33

ENSG00000137033 · protein coding · Open Targets profile

Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016, PubMed:19841166). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2- associated cytokines (PubMed:17853410, PubMed:18836528). Also involved in activation of mast cells, basophils, eosinophils and natural killer cells (PubMed:17853410, PubMed:18836528). Acts as an enhancer of polarization of alternatively activated macrophages (PubMed:19841166). Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528). Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity). {ECO:0000250|UniProtKB:Q8BVZ5, ECO:0000269|PubMed:16286016, ECO:0000269|PubMed:17853410, ECO:0000269|PubMed:18836528, ECO:0000269|PubMed:19841166}.

None of the 3 drugs recorded against IL33 is approved yet; 1 reached Phase 3

Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.

Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.

IL33: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody: Advanced Clinical, UniProt loc high conf, GO CC high conf

gnomAD loss of function constraint: o/e 1.3555999994277954 (upper bound 1.783400058746338). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of IL33's approved or late-stage drugs in the last three years.

1 of 10 trials of drugs against IL33 have sites only in United States

Registry trials of itepekimab, etokimab, torudokimab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 1 of 10 have all sites in one country.

Sites only in this groupSites here and elsewhere

Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.

3 trials of drugs against IL33 were stopped early

Terminated, withdrawn and suspended interventional trials of itepekimab, etokimab, torudokimab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 3 most recent of 3.

Ph3NCT07484230 brief why it stopped
withdrawn · 2026-08-13 · Sanofi · Itepekimab (SAR440340)
“Sponsor decision. Not related to safety concern.”
Ph2NCT03738423 brief why it stopped
terminated · 2022-06-10 · Regeneron Pharmaceuticals · matched by the registry's drug synonyms
“Lack of efficacy”
Ph2NCT03736967 brief why it stopped
terminated · 2021-11-01 · Regeneron Pharmaceuticals · matched by the registry's drug synonyms
“Lack of efficacy”

Paediatric incentives and obligations for IL33's drugs

For itepekimab, etokimab, torudokimab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

FDA pediatric target list: no · IL33 is not on the list
Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
EU paediatric investigation plan: yes · EMA/PE/0000229841 (itepekimab, Treatment of nasal polyposis): W: decision granting a waiver in all age groups for all conditions or indications, 21 Mar 2025
Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMA/PE/0000229841, 2026-11-11
EU orphan designation: no · No EU orphan designation names itepekimab, etokimab, torudokimab
Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
Authorised in the EU: no · EMA lists no centrally authorised medicine of itepekimab, etokimab, torudokimab
Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link
Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of itepekimab, etokimab, torudokimab
Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
Registered studies open to children: no · No interventional study of itepekimab, etokimab, torudokimab includes patients under 18
Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

All 3 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

Drug	Type	Highest stage	Indications	Source records
ITEPEKIMAB	Antibody	phase 3	chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, asthma, atopic eczema, bronchiectasis, chronic rhinosinusitis without nasal polyps, inflammation, allergic asthma	Open Targets · ChEMBL
ETOKIMAB	Antibody	phase 2	atopic eczema, peanut allergic reaction, asthma, dermatitis	Open Targets · ChEMBL
TORUDOKIMAB	Antibody	phase 2	atopic eczema	Open Targets · ChEMBL